TICKERNERD
Menu
ESLAESLAHealthcare · Biotechnology

ESLA Stock Forecast: Estrella Immunopharma, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.66
−1.99% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$29.3M
Ticker Nerd rank
26 / 100
Median analyst target
$12
Analysts covering
0
Revenue$0.0
Operating income−$2.1M
Net income−$2.3M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.9%
1M
−6.4%
YTD
−57.7%
1Y
−36.6%
From 52W high
−78.4%
From 52W low
+3.4%
$0.64
$3.05
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ESLA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Estrella Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Accruals
69
Value
44
Momentum
42
Growth
32
Revisions
30
Issuance
29
Volatility
26
Quality
11

Size (86): Smaller than most of the companies we track.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ESLA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ESLA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26ESLAHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Feb 2026D. Boral CapitalMaintainsBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy$8.00
28 Jan 2026D. Boral CapitalMaintainsBuy—
3 Nov 2025D. Boral CapitalMaintainsBuy—
12 Aug 2025D. Boral CapitalMaintainsBuy—
3 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
21 Feb 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ESLA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ESLA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Estrella Immunopharma, Inc. returned −36.6% against +17.5% for the S&P 500, dividends included.

ESLA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Oct 25Jan 26Apr 26Jul 26ESLAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ESLA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Estrella Immunopharma, Inc. (ESLA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
−3.9×

Cheaper than 96% of US stocks

EV / EBITDA
−2.2×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
126.0%

Higher than 97% of US stocks

Return on assets
−251.9%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Estrella Immunopharma, Inc. (ESLA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Estrella Immunopharma, Inc. has a market value of $29.3M and an enterprise value of $29.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$10.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$9.4M.

  • Estrella Immunopharma, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 43.0M.

  • Trailing P/E: −1.9×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Estrella Immunopharma, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

ESLA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ESLAEstrella Immunopharma, Inc.$29.3M
26
RNAZTransCode Therapeutics, Inc.$28.6M
22
IGCIGC Pharma, Inc.$28.8M
7
QNCXQuince Therapeutics, Inc.$28.9M
29
PLRZPolyrizon Ltd.$26.2M
12
CVMCEL-SCI Corp.$26.0M
35
NNVCNanoViricides, Inc.$25.9M
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Estrella Immunopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ESLA news & analysis

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Business Wire · 11 Aug 2026positive

Estrella Immunopharma announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its ongoing Phase I/II STARLIGHT-1 trial. The trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Why it matters — The addition of another clinical site may support patient recruitment and advancement of the STARLIGHT-1 trial for Estrella's lead CD19-targeted T-cell therapy candidate.

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Business Wire · 3 Aug 2026positive

Estrella Immunopharma announced the activation of Oregon Health & Science University as the third clinical site for its ongoing Phase I/II STARLIGHT-1 trial, which is evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Why it matters — For ESLA watchers, adding a third clinical site indicates continued enrollment expansion for the company's lead candidate EB103 in a key pivotal-stage trial.

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Business Wire · 29 July 2026positive

Estrella Immunopharma announced the activation of Baylor Scott & White Research Institute as a second clinical site for its Phase I/II STARLIGHT-1 trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Why it matters — Expanding to an additional clinical site can help accelerate enrollment and progress of the STARLIGHT-1 trial, a key pipeline program for Estrella.

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma

Business Wire · 24 July 2026positive

Estrella Immunopharma announced the first patient has been dosed in the dose-expansion phase of its STARLIGHT-1 Phase I/II trial evaluating EB103 in relapsed/refractory advanced B-cell non-Hodgkin's lymphoma.

Why it matters — The advancement to the dose-expansion phase represents clinical progress for Estrella's lead ARTEMIS® T-cell therapy candidate.

FAQ

Frequently asked questions about ESLA stock

How does Ticker Nerd's model rank ESLA?

As at 12 Sept 2026, Estrella Immunopharma, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the ESLA stock forecast for 2030?

No analyst covering Estrella Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has ESLA stock performed over the past year?

Estrella Immunopharma, Inc. returned -36.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Estrella Immunopharma, Inc. do?

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases.

What is the latest news on ESLA?

The most recent item we track (Business Wire, 11 Aug 2026): "Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma". Estrella Immunopharma announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its ongoing Phase I/II STARLIGHT-1 trial. The trial evaluates EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Company

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.

CEO Dr. Cheng Liu Ph.D. · United States · https://www.estrellabio.com